{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:36:00Z","timestamp":1792812960212,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107404","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:41:49Z","timestamp":1784853709000},"page":"107404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Tolebrutinib liver safety: A detailed overview"],"prefix":"10.1016","volume":"113","author":[{"given":"Christina R.","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Wallstroem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhad","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107404_bib0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug\u2013induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10\u2013year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.msard.2026.107404_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12876-021-01825-2","article-title":"Zanubrutinib\u2013induced liver injury: a case report and literature review","volume":"21","author":"Atallah","year":"2021","journal-title":"BMC. Gastroenterol."},{"key":"10.1016\/j.msard.2026.107404_bib0003","unstructured":"Bar-Or, A., Oh, J., Giovannoni, G., et al., 2026. Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study. https:\/\/www.abstractsonline.com\/pp8\/#!\/21408\/presentation\/971. San Diego, CA, USA. Presented at the ACTRIMS Forum 2026, February 5-7."},{"key":"10.1016\/j.msard.2026.107404_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug\u2013induced liver disease","volume":"42","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.msard.2026.107404_bib0005","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug\u2013induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.msard.2026.107404_bib0006","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/17425255.2025.2577677","article-title":"Modifying Hy's law and edish for the modern idiosyncratic DILI era","volume":"21","author":"Cohen","year":"2025","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.msard.2026.107404_bib0007","unstructured":"EMA, 2026. Cenrifki: EPAR \u2013 product information. https:\/\/www.ema.europa.eu\/en\/documents\/product\u2013information\/cenrifki\u2013epar\u2013product\u2013information_en.pdf (accessed 29 July 2026)."},{"key":"10.1016\/j.msard.2026.107404_bib0008","first-page":"16","article-title":"Guidance for industry: drug\u2013induced liver injury: premarketing clinical evaluation. U.S","year":"2009","journal-title":"Food Drug Adm."},{"key":"10.1016\/j.msard.2026.107404_bib0009","unstructured":"FDA, 2025. New drug application tolebrutinib tablets. https:\/\/download.open.fda.gov\/crl\/CRL_NDA219624_20251223.pdf. (accessed 29 July 2026)."},{"key":"10.1016\/j.msard.2026.107404_bib0010","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107404_bib0011","unstructured":"Genentech, 2023. Fenebrutinib Multiple Sclerosis Clinical Trial Program Update. https:\/\/www.gene.com\/media\/statements\/ps_113023. (accessed 29 July 2026)."},{"key":"10.1016\/j.msard.2026.107404_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS\u2019","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107404_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2026.107404_bib0014","unstructured":"InnoCare, 2022. Patient enrollment of phase II study evaluating orelabrutinib in multiple sclerosis paused. https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2022\/1223\/2022122301336.pdf (accessed 29 July 2026)."},{"key":"10.1016\/j.msard.2026.107404_bib0015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse\u2013independent progression vs relapse\u2013associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107404_bib0016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107404_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf062","article-title":"Five years of post\u2013marketing liver safety data from the tolvaptan risk evaluation and mitigation strategy","volume":"18","author":"Lohrmann","year":"2025","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.msard.2026.107404_bib0018","unstructured":"Merck, 2023. Initiation of new patients on evobrutinib paused in the U.S.; fully enrolled phase III evobrutinib studies continue. https:\/\/www.merckgroup.com\/press\u2013releases\/2023\/apr\/en\/Evobrutinib\u2013update\u2013FDA\u2013EN.pdf (accessed 29 July 2026)."},{"key":"10.1016\/j.msard.2026.107404_bib0019","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo\u2013controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107404_bib0020","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107404_bib0021","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/cts.13162","article-title":"Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)","volume":"15","author":"Owens","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.msard.2026.107404_bib0022","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain\u2013penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double\u2013blind, placebo\u2013controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107404_bib0023","unstructured":"Reich, D.S., Bar-Or, A., Vermersch, P., et al., 2026. Efficacy and Safety of Tolebrutinib in Primary Progressive Multiple sclerosis: Primary Results of the Phase 3 PERSEUS Study. https:\/\/www.abstractsonline.com\/pp8\/#!\/21408\/presentation\/972. San Diego, CA, USA. Presented at the ACTRIMS Forum 2026, February 5-7."},{"key":"10.1016\/j.msard.2026.107404_bib0024","unstructured":"Sanofi, 2022. Patient enrollment of phase III tolebrutinib trials paused in the U.S. https:\/\/www.sanofi.com\/en\/media\u2013room\/press\u2013releases\/2022\/2022\u201306\u201330\u201305\u201330\u201300\u20132471767 (accessed 29 July 2026)."},{"key":"10.1016\/j.msard.2026.107404_bib0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.27034","article-title":"Smouldering\u2013associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107404_bib0026","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000502605","article-title":"Severe hepatotoxicity due to ibrutinib with a review of published cases","volume":"13","author":"Tafesh","year":"2019","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.msard.2026.107404_bib0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.msard.2026.107404_bib0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drudis.2019.09.022","article-title":"Drug\u2013induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity","volume":"25","author":"Thakkar","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.msard.2026.107404_bib0029","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1212\/01.wnl.0000238515.27055.62","article-title":"Liver test abnormalities in multiple sclerosis: findings from placebo\u2013treated patients","volume":"67","author":"Tremlett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107404_bib0030","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1080\/14796694.2025.2509409","article-title":"TURALIO\u00ae risk evaluation and mitigation strategy (tREMS) program: 5\u2013year retrospective hepatic safety assessment","volume":"21","author":"Waheed Rajper","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.msard.2026.107404_bib0031","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."}],"updated-by":[{"DOI":"10.1016\/j.msard.2026.107669","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000}},{"DOI":"10.1016\/j.msard.2026.107669","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:47:37Z","timestamp":1787921257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S2211034826004396"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107404","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolebrutinib liver safety: A detailed overview","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107669","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107404"}}